DLDong Woo Lee

Dong Woo Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dong Woo Lee has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Yoon Jeong Park

    Central Research Institute, Nano Intelligent Biomedical Engineering Corporation (NIBEC), Seoul, 03127, Republic of Korea; Department of Dental Regenerative Biotechnology and Dental Research Institute, School of Dentistry, Seoul National University, Seoul, 03080, Republic of Korea

    5 shared publications
  • Chong-Pyoung Chung

    Central Research Institute Nano Intelligent Biomedical Engineering Corporation (NIBEC) Seoul Korea

    3 shared publications
  • Hee-Seung Han

    Department of Periodontology Korea University Anam Hospital Seoul Republic of Korea

    3 shared publications
  • Jue-Yeon Lee

    Central Research Institute, Nano Intelligent Biomedical Engineering Corporation (NIBEC), School of Dentistry, Seoul National University, Seoul 03080, Korea

    3 shared publications
  • Young-Dan Cho

    Department of Periodontology, School of Dentistry and Dental Research Institute Seoul National University and Seoul National University Dental Hospital Seoul Republic of Korea

    3 shared publications
  • Chong Pyung Chung

    Central Research Institute, Nano Intelligent Biomedical Engineering Corporation (NIBEC), Seoul, 03127, Republic of Korea; Department of Periodontology, School of Dentistry, Seoul National University, Seoul, 03080, Republic of Korea

    2 shared publications

Latest Publications

  • Open Access

    BMP9-loaded collagen scaffold promotes periodontal regeneration via microenvironmental modulation of PDLSCs and macrophages

    by Dong Woo Lee, Hee-Seung Han, Yu-Bin Kim, Sanghui Seok, Gookjin Yoon, Hyunjae Kim, Jin Wook Yang, Suhyun Park, Yang Jo Seol, Sungtae Kim, et al.

  • Open Access

    Lymph node-targeted mRNA delivery of fine-tuned peptide-nanocomplexes for SARS-CoV-2 Vaccination

    by Hayoon Jeong, Gookjin Yoon, Dong Woo Lee, Hansang Yu, Yu-Bin Kim, Nayeong Kim, Jaeseok Choi, Eunkyung Shin, You-Jin Kim, Hye-Sook Jeong, et al.


  • Open Access

    Bone Morphogenetic Protein ( BMP ) 9 Outperforms BMP2 in Osteogenesis and Osseointegration: In Vitro and In Vivo

    by Hee‐Seung Han, Dong Woo Lee, Yu‐Bin Kim, Sanghui Seok, Jeong Yeon Park, Sungtae Kim, Jue Yeon Lee, Yoon Jeong Park, Chong Pyung Chung, Young‐Dan Cho

    Objectives: This study compared the osteogenic mechanisms and preclinical efficacy of bone morphogenetic protein 9 (BMP9) and BMP2 in vitro and in a beagle peri‐implant defect model in vivo. Materials and Methods: In vitro, MC3T3‐E1 preosteoblasts were treated with BMP2 or BMP9 to assess osteogenic gene expression ( Col1, Runx2, Alp, Ocn ) by real‐time PCR, Smad1/5/9 phosphorylation by western blotting, and osteogenesis by alkaline phosphatase (ALP) and Alizarin Red S staining. In vivo, saddle‐type peri‐implant defects were created in beagle mandibles and treated with a collagenated xenograft matrix with or without BMP2 or BMP9 (150 μg/site). After 8 weeks, implant stability, micro‐CT, histomorphometry, and osseointegration parameters were analyzed. Results: BMP9 significantly enhanced osteogenic gene expression, Smad1/5/9 phosphorylation, ALP activity, and mineralization compared to BMP2. In vivo, BMP9 yielded the highest implant stability values, greater defect fill, and higher bone volume fraction, bone mineral density, and bone‐to‐implant contact. Conclusions: BMP9 showed stronger osteoinductive potential than BMP2, resulting in improved bone regeneration and osseointegration. These findings suggest that BMP9 is a promising growth factor for improving dental implant outcomes.


  • Open Access

    A Multifunctional β‐Defensin‐3 Mimetic Peptide Modulates Host–Biofilm Interactions and Reduces Bone Loss in Periodontitis

    by Beom Soo Jo, Dong Woo Lee, Ji‐Young Lee, Sanghui Seok, Yu‐Bin Kim, Jue‐Yeon Lee, Shin‐Young Park, Young Dan Cho, Yang Jo Seol, Yoon Shin Park, et al.

    Aim: This study evaluated the potential of a beta‐defensin‐3 mimetic peptide (BDMP), a synthetic cell‐penetrating peptide with antimicrobial and immunomodulatory properties, as an adjunctive therapeutic approach for periodontitis. Methods: BDMP was formulated in a hydroxyethyl cellulose (HEC) gel and assessed for binding affinity, release kinetics, and ability to penetrate cells and gingival tissues. Anti‐inflammatory and osteoclast‐related signaling pathways were examined in vitro using RAW264.7 macrophages stimulated with lipopolysaccharide (LPS). Effects on osteogenic recovery were evaluated in periodontal ligament stem cells (PDLSCs) under inflammatory conditions. Antimicrobial activity against multispecies biofilms was analyzed by confocal microscopy. In a ligature‐induced experimental periodontitis model in beagle dogs, BDMP gel was compared with a subgingival instrumentation (SI)‐only (standard‐of‐care) control, and minocycline gel was included as an active adjunctive comparator. Clinical parameters, inflammatory markers, microbial load, radiographs, micro‐CT images, and histology were evaluated. Results: In vitro, BDMP reduced histone deacetylase 5 (HDAC5) phosphorylation and attenuated downstream NF‐κB–associated inflammatory signaling without altering upstream kinase activity. BDMP decreased osteoclast differentiation, reduced inflammatory cytokine transcription, and partially restored osteogenic capacity in LPS‐stimulated PDLSCs. BDMP also demonstrated broad‐spectrum antimicrobial activity and disrupted mature multispecies biofilms. In vivo, BDMP resulted in greater reductions in gingival inflammation, bleeding, IL‐1β levels, and oral spirochetes over 12 weeks compared with the SI‐only control. Radiographic images provided qualitative support for reduced bone loss, which was corroborated by micro‐CT and histology, indicating attenuation of alveolar bone resorption. When compared with the combination of SI and minocycline arm, BDMP showed comparable or greater improvements in several inflammatory and microbiological parameters. Conclusion: BDMP exhibited sustained antimicrobial and anti‐inflammatory activity and attenuated bone loss in a beagle periodontitis model when used alongside standard SI therapy. These findings support BDMP as a promising adjunctive therapeutic candidate for managing periodontal inflammation and biofilm‐associated disease, although further studies are needed to confirm long‐term safety and to define its mechanistic contributions to periodontal tissue preservation.

  • Open Access

    BMP9 promotes peri-implant osseointegration in beagle defects

    by Hee-Seung Han, Dong Woo Lee, Sungtae Kim, Jue Yeon Lee, Yoon Jeong Park, Chong Pyung Chung, Young-Dan Cho

    Han HS, et al. J Periodontal Implant Sci. 2026 ;56:e14. https://doi.org/10.5051/jpis.2505500275